This study focused on engineering an antagonistic anti-c-MET antibody capable of blocking HGF/c-MET signaling and inducing the killing of MET-overexpressing cancer cells through antibody-dependent cellular cytotoxicity (ADCC). The gene discussed is MET; the disease is cancer.